IDEAYA Biosciences, Inc. (IDYA): Price and Financial Metrics


IDEAYA Biosciences, Inc. (IDYA): $13.88

0.06 (+0.43%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

IDYA POWR Grades


  • IDYA scores best on the Value dimension, with a Value rank ahead of 67.04% of US stocks.
  • The strongest trend for IDYA is in Growth, which has been heading down over the past 179 days.
  • IDYA ranks lowest in Momentum; there it ranks in the 4th percentile.

IDYA Stock Summary

  • IDYA's went public 2.85 years ago, making it older than merely 8.48% of listed US stocks we're tracking.
  • Of note is the ratio of IDEAYA Biosciences Inc's sales and general administrative expense to its total operating expenses; merely 11.08% of US stocks have a lower such ratio.
  • With a price/sales ratio of 16.3, IDEAYA Biosciences Inc has a higher such ratio than 91.29% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to IDEAYA Biosciences Inc, a group of peers worth examining would be PLRX, DTIL, JNCE, WVE, and SRPT.
  • IDYA's SEC filings can be seen here. And to visit IDEAYA Biosciences Inc's official web site, go to www.ideayabio.com.

IDYA Valuation Summary

  • In comparison to the median Healthcare stock, IDYA's price/earnings ratio is 182.47% lower, now standing at -30.1.
  • IDYA's price/earnings ratio has moved down 24.4 over the prior 28 months.
  • IDYA's EV/EBIT ratio has moved down 22.2 over the prior 28 months.

Below are key valuation metrics over time for IDYA.

Stock Date P/S P/B P/E EV/EBIT
IDYA 2021-08-31 25.4 3.8 -30.1 -27.2
IDYA 2021-08-30 24.7 3.7 -29.3 -26.5
IDYA 2021-08-27 24.8 3.7 -29.3 -26.5
IDYA 2021-08-26 24.3 3.6 -28.7 -25.9
IDYA 2021-08-25 25.0 3.7 -29.6 -26.8
IDYA 2021-08-24 25.6 3.8 -30.3 -27.5

IDYA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • IDYA has a Quality Grade of C, ranking ahead of 32.42% of graded US stocks.
  • IDYA's asset turnover comes in at 0.113 -- ranking 252nd of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows IDYA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.113 1 -0.163
2021-03-31 0.096 1 -0.224
2020-12-31 0.088 1 -0.295
2020-09-30 0.051 1 -0.455
2020-06-30 0.000 NA -0.699
2020-03-31 0.000 NA -0.647

IDYA Price Target

For more insight on analysts targets of IDYA, see our IDYA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $30.78 Average Broker Recommendation 1.28 (Strong Buy)

IDYA Stock Price Chart Interactive Chart >

Price chart for IDYA

IDYA Price/Volume Stats

Current price $13.88 52-week high $28.00
Prev. close $13.82 52-week low $8.14
Day low $13.27 Volume 824,800
Day high $14.17 Avg. volume 350,830
50-day MA $10.88 Dividend yield N/A
200-day MA $17.26 Market Cap 536.32M

IDEAYA Biosciences, Inc. (IDYA) Company Bio


IDEAYA Biosciences, Inc. develops cancer therapeutics. It is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company operates and manages its business as one operating and reportable segment, which is the business of research and development for oncology-focused precision medicine. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.


IDYA Latest News Stream


Event/Time News Detail
Loading, please wait...

IDYA Latest Social Stream


Loading social stream, please wait...

View Full IDYA Social Stream

Latest IDYA News From Around the Web

Below are the latest news stories about IDEAYA Biosciences Inc that investors may wish to consider to help them evaluate IDYA as an investment opportunity.

ProQR (PRQR) Reports Q4 Loss, Misses Revenue Estimates

ProQR (PRQR) delivered earnings and revenue surprises of -15.38% and 69.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

Cue Biopharma, Inc. (CUE) Stock Jumps 6.5%: Will It Continue to Soar?

Cue Biopharma, Inc. (CUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Yahoo | February 15, 2022

IDEAYA Biosciences (NASDAQ:IDYA) investors are sitting on a loss of 20% if they invested a year ago

The simplest way to benefit from a rising market is to buy an index fund. But if you buy individual stocks, you can do...

Yahoo | February 14, 2022

IDEAYA Biosciences to Participate in Investor Conferences in February 2022

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in an investor conference in February 2022.

Yahoo | February 1, 2022

IDEAYA Advances IDE161 Into IND-Enabling Studies, Exercises Licensing Option For PARG Inhibitors

IDEAYA Biosciences Inc (NASDAQ: IDYA) has initiated IND-enabling studies for IDE161, a potential first-in-class PARG inhibitor development candidate. IDEAYA is targeting an IND submission for IDE161 in Q4 Of 2022. The company plans to evaluate IDE161 in patients having tumors with homologous recombination deficiencies, including BRCA1 and BRCA2, and potentially other genetic alterations identified through IDEAYA's biomarker discovery platform. The company also exercised its option for an exclusi

Yahoo | January 31, 2022

Read More 'IDYA' Stories Here

IDYA Price Returns

1-mo 33.08%
3-mo 21.33%
6-mo -40.40%
1-year -35.47%
3-year 41.49%
5-year N/A
YTD -41.29%
2021 68.86%
2020 86.67%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5101 seconds.